Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Toumy Guettouche, Max van Min, Andy Ferrin, Eric Banks, More


The Children's Hospital of Philadelphia has named Toumy Guettouche a senior scientist and director of sequencing within CHOP's Center for Applied Genomics. He reports to Hakon Hakonarson, who heads the center. Guettouche joins CHOP from the University of Miami, Miller School of Medicine, where he was most recently the director of research and development in the CLIA laboratory of the University's Clinical and Translational Genetics. His previous roles at the University of Miami include director of genome technology assessment and implementation, and director of the oncogenomics core facility. He holds a PhD in biochemistry and molecular biology from the University of Miami.

Cergentis, a spin-off from the Royal Netherlands Academy of Arts and Sciences that was founded in 2012, has disclosed its management team (see story, this issue).

Max van Min, co-inventor of the firm's targeted locus amplification technology, is CEO. Previously, he held management positions at Keygene and DSM.

Erik Splinter is CTO. Previously, he worked on the development of technologies to analyze 3D structures of the human genome at Erasmus MC and the Hubrecht Institute.

Wouter de Laat is principal scientist. He is a group leader at the Hubrecht Institute and a professor in biomedical genomics at the University Medical Center Utrecht.

Elzo de Wit is head of bioinformatics. He performed his doctoral training in computational biology at the Netherlands Cancer Institute and specializes in developing software tools to analyze genomics methods.

Andy Ferrin has left Golden Helix to become a sales executive at Oracle Health Sciences. Ferrin had served as executive vice president of sales, business development, and services at Golden Helix, a Bozeman, Mont.-based bioinformatics company, for the past six years.

Eric Banks is now the team leader of the Broad Institute's Genome Sequencing and Analysis program. He is taking over for Mark DePristo, who is now VP of informatics at SynapDx.

Before joining the Broad in 2009, Banks earned an ME from the Massachusetts Institute of Technology and a PhD in computational biology from Princeton University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.